NEW YORK (GenomeWeb) – AMD Insight today announced it has exclusively licensed from ArcticDx the commercial rights in Canada for the Macula Risk PGx test.

Macula Risk PGx is a prognostic and pharmacogenetic DNA test for evaluating a patient's risk of progressing to advanced age-related macular degeneration and aids in choosing appropriate vitamin formulations for AMD based on the patient's genetic risk profile.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.